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BACKGROUND AND PURPOSE
3-Iodothyronamine (T1AM), an endogenous derivative of thyroid hormones, is regarded as a rapid modulator of behaviour
and metabolism. To determine whether brain thyroid hormone levels contribute to these effects, we investigated the effect of
central administration of T1AM on learning and pain threshold of mice either untreated or pretreated with clorgyline
(2.5 mg·kg-1, i.p.), an inhibitor of amine oxidative metabolism.
EXPERIMENTAL APPROACH
T1AM (0.13, 0.4, 1.32 and 4 mg·kg-1) or vehicle was injected i.c.v. into male mice, and after 30 min their effects on memory
acquisition capacity, pain threshold and curiosity were evaluated by the following tests: passive avoidance, licking latency on
the hot plate and movements on the hole-board platform. Plasma glycaemia was measured using a glucorefractometer. Brain
levels of triiodothyroxine (T3), thyroxine (T4) and T1AM were measured by HPLC coupled to tandem MS. ERK1/2 activation
and c-fos expression in different brain regions were evaluated by Western blot analysis.
RESULTS
T1AM improved learning capacity, decreased pain threshold to hot stimuli, enhanced curiosity and raised plasma glycaemia in
a dose-dependent way, without modifying T3 and T4 brain concentrations. T1AM effects on learning and pain were abolished
or significantly affected by clorgyline, suggesting a role for some metabolite(s), or that T1AM interacts at the rapid
desensitizing target(s). T1AM activated ERK in different brain areas at lower doses than those effective on behaviour.
CONCLUSIONS AND IMPLICATIONS
T1AM is a novel memory enhancer. This feature might have important implications for the treatment of endocrine and
neurodegenerative-induced memory disorders.
Abbreviations
CREB, cyclic AMP-responsive element binding; PBST, PBS plus Tween; T1AM, 3-iodothyronamine; T3, triiodothyroxine;
T4, thyroxine; TA1 receptor, trace amine-associated receptor 1
BJP British Journal ofPharmacology
DOI:10.1111/j.1476-5381.2012.02137.x
www.brjpharmacol.org
354 British Journal of Pharmacology (2013) 168 354–362 © 2012 The Authors
British Journal of Pharmacology © 2012 The British Pharmacological Society
Introduction
3-Iodothyronamine (T1AM) is an endogenous primary amine
probably produced through thyroid hormone metabolism
(Scanlan, 2009; Piehl et al., 2011). T1AM circulates in healthy
rodents and humans (Saba et al., 2010; Galli et al., 2012) but
it concentrates in tissues, particularly in the liver and brain
(Saba et al., 2010). Recently, several studies have explored the
consequences of administering T1AM directly into the brain.
T1AM injected i.c.v. rapidly induces metabolic effects, includ-
ing a reduction of body temperature (Doyle et al., 2007),
modification of food intake and hyperglycaemia (Manni
et al., 2012). T1AM effects were not linearly related to the
dosage and depended on the animal species and administra-
tion route (Dhillo et al., 2008; Klieverik et al., 2009). We have
recently reported that 1.32 mg·kg-1 T1AM injected i.c.v. into
fasted mice produced hypophagia and hyperglycaemia, while
it reduced plasma fT3 and fasting-induced c-fos activation
(Manni et al., 2012). Both hypophagia and fT3 reduction
were not linearly related to T1AM doses and they were pre-
vented by in vivo treatment with clorgyline, an inhibitor of
oxidative deamination, the major pathway of T1AM catabo-
lism (Saba et al., 2010), suggesting the involvement of rapid
desensitizing targets and/or interference with neuromedia-
tors producing opposing effects on behaviour. In fact, elec-
trophysiological experiments suggest that T1AM affects the
response to catecholamines and other neurotransmitters,
acting as a specific inhibitor of dopamine and noradrenaline
re-uptake and of monoamine transport into synaptic vesicles
(Snead et al., 2007). Therefore, T1AM might be regarded as a
neuromodulator.
In the present paper, we investigated whether T1AM is
able to produce specific neurological effects such as the modi-
fication of memory acquisition and pain threshold in mice,
and whether these effects are modified under conditions of
MAO inhibition by clorgyline and whether they were associ-
ated with changes in triiodothyroxine (T3) and thyroxine
(T4) brain levels.
With this aim, we evaluated the behaviour of mice
injected i.c.v. with T1AM (0.13, 0.4, 1.32 and 4 mg·kg-1) in
the passive avoidance test and in the novel object recogni-
tion task, as well as the effects of T1AM on pain threshold,
exploratory activity and plasma glycaemia. In parallel
experiments, the activation of typical signalling proteins
involved in memory acquisition and pain perception,
including pERK, pAkT, c-fos and pCREB, were measured in
specific brain areas. Brain levels of T3 and T4 and of T1AM
were also determined following injection of T1AM at the
lowest effective dose.
Methods
Animals
One hundred and twenty male mice (CD1 strain; 20–30 g)
from the Morini breeding farm (San Polo d’Enza, Italy) were
used. The cages were placed in the experimental room 24 h
before the tests for adaptation. Animals were kept at 23 1°C
with a 12 h light–dark cycle (light on at 07:00 h) and were fed
a standard laboratory diet with water ad libitum. Experiments
and animal use procedures were in accordance with the
National Institutes of Health Guide for the Care and Use of
Laboratory Animals (NIH Publications No. 80-23, revised
1996). The experimental protocols were approved by the
Animal Care Committee of the Department of Pharmacology,
University of Florence, in compliance with the European
Convention for the Protection of Vertebrate Animals used for
Experimental and Other Scientific Purposes (ETS No. 123)
and the European Community Council Directive of 24
November 1986 (86/609/EEC). The authors further attest that
all efforts were made to minimize the number of animals used
and their suffering. All studies involving animals are reported
in accordance with the ARRIVE guidelines (Kilkenny et al.,
2010; McGrath et al., 2010).
I.c.v. injection technique
I.c.v. administration was performed under light ether anaes-
thesia according to the method described by Haley and
McCormick (1957), with minor modifications. The depth of
anaesthesia was checked by monitoring the respiratory rate
(which was reduced within 2 min) and testing for lack of a
pain response to gentle pressure on the hind paws. The head
of the anaesthetized mouse was grasped firmly and the needle
of a 10 mL microsyringe was inserted perpendicularly 2 mm
through the skull into the brain. Ten microlitres of solution
was then slowly injected (in 20 s) into a lateral ventricle. The
injection site was 1 mm to the left of the midpoint, on a line
drawn through to the anterior base of the ears. Immediately
after needle removal, the animal remained quiet for approxi-
mately 1 min and then resumed its normal activity. To ascer-
tain that solutions were administered exactly into the
cerebral ventricle, some mice were injected with 10 mL of 1:10
India ink and their brains were examined macroscopically
after sectioning. The accuracy of the injection technique was
confirmed to 95%.
Behavioural tests
The passive avoidance paradigm. This test was performed
according to the step-through method described by Jarvik
and Kopp (1967). The experimental apparatus consisted of a
two-compartment acrylic box with a lighted compartment
connected to a darkened one by a guillotine door. The dark
chamber was constructed with a pitfall floor. When entering
this chamber in the training session, the mice receive a non-
painful punishment consisting of a fall (from 40 cm) into a
cold water bath (10°C). The test was then repeated 1 and 24 h
after the training session. Before the trials, the mice were
removed from the cage and injected i.c.v. with 10 mL of
vehicle (0.5% DMSO) or T1AM (0.13, 0.40, 1.32 and 4 mg·kg-1;
n = 20 for each treatment). Additional mice were pretreated
with an i.p. injection of clorgyline (2.5 mg·kg-1) and then
received either vehicle or T1AM i.c.v. T1AM was kindly pro-
vided by Dr Thomas Scanlan (Portland, OR, USA) and was
dissolved in vehicle. Thirty minutes after i.c.v. injections, the
mice were placed on an illuminated platform (60 W, 840 lux)
and allowed to enter the dark compartment (training
session). Because mice prefer dark to light, they usually
entered the dark compartment within 5 s. Mice not entering
the dark compartment within 60 s during the training session
were excluded from the experiment. The extent of punish-
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ment memory was expressed as the difference in seconds
between training and retention latencies. The latter was
measured 1 and 24 h after the training session. In the 1 h and
24 h tests, each animal was placed on the platform and the
latency to enter the dark compartment was measured up to a
maximum of 300 s.
The novel object recognition task. Experiments were carried
out as described by Ennaceur and Delacour (1988), with
minor modifications. The mice were subjected to the proce-
dure separately and care was taken to remove any olfactory/
taste cues by cleaning the arena and test objects with
alcohol between trials. Each mouse completed one session
with three successive trials. In trial 1, habituation phase,
24 h before the test day the mouse was placed at the centre
of the empty ‘open-field’ arena, located in a sound-
attenuated room under dimmed lighting for 2 min. On the
following day, mice (n = 20) were injected with T1AM
(1.32 mg·kg-1, a dose selected on the basis of our previous
experiments) 30 min before the second trial (familiariza-
tion). During this trial (trial 2), the sample phase, two
objects (such as plastic cubes or cylinders) were placed in
opposite corners of the box and the mouse was allowed to
explore them. After 24 h, each mouse was again placed in
the test arena for 5 min (trial 3) in the presence of one of the
familiar objects and of a novel object, and the time spent
exploring both objects was again recorded. Object position
and presentation order were randomized to prevent bias
from order or place preference. Each trial lasted 5 min, with
a 3 min inter-trial interval (ITI). During the ITI, the mouse
was removed from the testing box and placed in a holding
cage. Exploration was defined as the state in which the
mouse’s nose was kept within 2 cm of the object. Locomotor
activity in the arena was measured as the times of grid
crossing.
The hole-board test. The hole-board test was performed
according to Galeotti et al. (2006). The experimental setting
consisted of a 40 cm square plane with 16 flush mounted
cylindrical holes (3 cm diameter) distributed four by four in
an equidistant, grid-like manner. Mice were placed in the
centre of the board one by one and allowed to move about
freely for a period of 10 min. Two electric eyes, crossing the
plane from midpoint to midpoint of the opposite sides, thus
dividing the plane into four equal quadrants, automatically
signalled mouse movements (locomotor activity). Miniature
photoelectric cells, in each of the 16 holes, recorded hole
exploration. Animals were injected i.c.v. with vehicle or
T1AM at dosages of 0.4, 1.32 or 4 mg·kg-1 (n = 20 in each
group) and tested 30 min after i.c.v. injections.
The hot plate. After the mice had been introduced to a hot
plate device (51.5  1°C), the latency of a flinching or
jumping response was measured. The cut-off time was set at
45 s to minimize skin damage. Animals were injected i.c.v.
with vehicle or T1AM at dosages of 0.13, 0.4, 1.32 and
4 mg·kg-1 (n = 20 in each group). Additional mice were pre-
treated with clorgyline (2.5 mg·kg-1, i.p.) before receiving
either vehicle or T1AM i.c.v. Measurements were performed
30 min after i.c.v. injections.
T1AM-activated signalling in brain
Preparation of mouse brain tissue. Male mice (mean weight,
23  3 g) were removed from the cage and injected i.c.v.
under light anaesthesia with 10 mL of vehicle or T1AM (0.044,
0.13 and 1.32, mg·kg-1). Mice (n = 5 for each treatment) were
then killed by decapitation, within 30 min of i.c.v. injections.
The skull was opened with scissors and the brain surface was
cooled down by exposing it to liquid nitrogen vapours for
1–2 s. The brain was excised and the forebrain was divided
into two parts: frontal cortex and diencephalon. The hippoc-
ampus and amygdala were then quickly removed. The
hypothalamus was separated from thalamus, and all tissues
were flash-frozen in liquid nitrogen and stored at -80°C until
use.
Brain samples were homogenized in homogenization
buffer containing (in mM): 50 Tris–HCl (pH 7.5), 150 NaCl, 1
EDTA, 5 sodium pyrophosphate, 10 b-glycerophosphate, 1
Na3VO4, 0.2 PMSF, 25 mg·mL-1 leupeptin, 10 mg·mL-1 apro-
tinin and 0.1% SDS. Homogenates were then centrifuged at
1000¥ g for 10 min at 4°C to remove cell debris, and super-
natants (brain lysates) were used for Western blot analysis.
Western blot analysis
Brain lysates (20 mg) were separated on 10% SDS-PAGE and
transferred into nitrocellulose membranes (120 min at 100 V)
using standard procedures. Membranes were blocked in PBST
(PBS containing 0.1% Tween) containing 5% non-fat dry milk
for 60 min. Following washing, blots were incubated over-
night at 4°C with specific antibody against ERK1/2 phospho-
rylated on Thr202/Tyr204 (pERK1/2, Cell Signaling Technology),
c-fos (Santa Cruz Biotechnology, Santa Cruz, CA, USA), pAkt
or pCREB (Cell Signalling Technology, Danvers, MA, USA).
All primary antibodies were diluted in PTBS containing 3%
albumin. After being washed with PBST, the nitrocellulose
membrane was incubated with polyclonal goat anti-rabbit
HRP-conjugated secondary antisera (1:2000, diluted in PTBS
containing 5% non-fat dry milk) and left for 1 h at room
temperature. Blots were then extensively washed and devel-
oped using an enhanced chemiluminescence detection
system (Pierce Scientific, Rockford, IL, USA). Exposition and
developing time were standardized for all blots. Densitomet-
ric analysis of scanned images was performed on a Macintosh
iMac computer using the public domain NIH Image program.
a-Tubulin (anti-a-tubulin 05–829, Millipore Corporation,
Billerica, MA, USA) was used as loading control. Protein con-
centration was quantified using Bradford’s method (protein
assay kit, Bio-Rad Laboratories, Segrate, Milan, Italy).
Assay of T1AM and thyroid hormone
brain concentration
Mice (n = 6) were killed by decapitation 30 min after T1AM
(1.32 mg·kg-1) or vehicle injection. The brain was isolated and
quickly frozen at -80°C. T1AM, T4 and T3 were extracted and
their levels were measured by HPLC coupled to tandem MS,
as described previously (Saba et al., 2010).
Measurement of plasma glycaemia. Mice were injected i.c.v.
with vehicle or T1AM at dosages of 0.13, 0.4 and 1.32 mg·kg-1
(n = 5 in each group). After 30 min, the tail vein was punc-
tured and drops of blood were collected to measure glycaemia
by a glucorefractometer.
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Statistical analysis
Data are expressed as mean  SEM of independent experi-
ments. Statistical analysis was performed by one-way
ANOVA, followed by Student–Newman–Keuls multiple com-
parison post hoc test. When the experimental setting included
only two groups, unpaired t-test was used. The threshold of
statistical significance was set at P < 0.05. Data analysis was
performed by GraphPad PRISM 5.0 statistical program (Graph-
Pad Software, San Diego, CA, USA).
Results
T1AM increased retention and consolidation
time in the passive avoidance paradigm
As described in the Methods section, retention sessions of the
passive avoidance test were performed 1 and 24 h after the
T1AM injection. Following administration of 0.4 and
0.13 mg·kg-1 T1AM, the latency to enter the dark compart-
ment was increased either in the 1 or the 24 h retention
session, but the difference versus the control group did not
reach the threshold of statistical significance. However, a
significantly higher latency to enter the dark compartment
was observed after 1.32 and 4 mg·kg-1 T1AM, both at 1 and
24 h (P < 0.001 and P < 0.05 vs. vehicle-treated mice respec-
tively) (Figure 1A).
T1AM improved memory acquisition: the
object recognition task
As 1.32 mg·kg-1 was the lowest effective dose in the passive
avoidance test, we next verified whether the pro-cognitive
effect of this dose was confirmed in another test, the novel
object recognition task, which is based on the natural ten-
dency of rodents to explore unfamiliar objects (Ennaceur and
Delacour, 1988).
As shown in Figure 2, mice treated with vehicle spent the
same amount of time exploring the familiar and the novel
object, while mice injected i.c.v. with 1.3 mg·kg-1 T1AM
showed significantly (P < 0.001) enhanced exploratory pref-
erence for the novel object in the 24 h retention test
(Figure 2A). At this dose, T1AM did not increase locomotor
activity (Figure 2B).
T1AM increased exploratory activity: the
hole-board test
Memory acquisition is facilitated by increased curiosity. Our
results demonstrated that mice injected i.c.v. with T1AM
(1.32 and 4 mg·kg-1) showed significantly increased explora-
tory activity (P < 0.05 vs. vehicle-injected mice), while this
effect was not detected in mice injected with 0.4 mg·kg-1
T1AM (Figure 3).
T1AM increased pain sensitivity
As the response to the passive avoidance and object recogni-
tion tests may be affected by an analgesic action, we next
Figure 1
(A) Mice were injected i.c.v. with T1AM (0.13, 0.4, 1.32 or 4 mg·kg-1) or with vehicle (Veh) and subjected to the passive avoidance test as described
in the Methods section. Results are expressed as mean  SEM; n = 20 in each group; *P < 0.05; ***P < 0.001 versus vehicle. (B) Mice pretreated
with clorgyline (2.5 mg·kg-1, i.p.), received either vehicle (Veh) or T1AM (0.4 or 1.32 mg·kg-1) i.c.v and were then subjected to the passive
avoidance test as described in the Methods section. Results are expressed as mean  SEM; n = 10 in each group.
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checked whether T1AM had any effect on the pain threshold
by investigating the latency to licking of mice injected i.c.v.
with T1AM and then located on the hot plate. As shown in
Figure 4, at doses that proved to be effective in the passive
avoidance test (1.32 and 4 mg·kg-1), T1AM significantly
reduced the threshold of pain perception to hot insults (P <
0.01 and P < 0.05 vs. vehicle respectively). Interestingly, the
hyperalgesic effect of T1AM was maintained at 0.4 mg·kg-1 but
it was lost at 0.132 mg·kg-1 (Figure 4).
Effect of clorgyline pretreatment on the
response to T1AM
Oxidative deamination by amine oxidases appears to be the
chief metabolic pathway for T1AM (Wood et al., 2009; Saba
et al., 2010), while other possible modifications are repre-
sented by deiodination (Piehl et al., 2008) and sulphorylation
(Pietsch et al., 2007). Therefore, it seemed interesting to
investigate whether the pro-learning and hyperalgesic effects
of T1AM were affected by the MAO inhibitor clorgyline,
which was administered i.p. at a dose of 2.5 mg·kg-1 (prelimi-
nary experiments showed that i.p. injection of vehicle had no
effect either in the vehicle group or in the T1AM-treated
group).
In the passive avoidance paradigm, the effect of T1AM
was lost after pretreatment with clorgyline (Figure 1B). With
regard to pain threshold experiments (Figure 4B), in the pres-
ence of clorgyline T1AM still produced a hyperalgesic action,
but the dose–response relationship was modified, because a
significant effect was detected only with 0.134 mg·kg-1 T1AM
(P < 0.05 vs. vehicle), but not with higher concentrations.
Notably, clorgyline treatment per se appeared to increase pain
sensitivity, because latencies were in general lower (P < 0.05)
than those observed in the previous set of experiments
(Figure 4A)
T1AM raised plasma glycaemia
Plasma glycaemia is sometimes regarded as a fingerprint of
T1AM effects. This was confirmed in the present investigation
because i.c.v. T1AM injection increased blood glucose
concentration at doses ranging from 0.13 to 1.32 mg·kg-1
(Figure 5). So, hyperglycaemia occurred even at doses that did
not produce any behavioural effect. Quantitative analysis
showed that the EC50 values for the effects on memory, curi-
osity and pain threshold ranged from 0.67 to 1.06 mg·kg-1.
The potency of T1AM in raising plasma glycaemia appears to
be even higher, as even the lowest dose used (0.132 mg·kg-1)
produced a maximum response.
T1AM induced ERK1/2 phosphorylation in
different cerebral areas
Memory acquisition and storage are typically associated with
increased ERK1/2 phosphorylation and increased expression
of transcription factors c-fos and pCREB. After treatment with
1.32 mg·kg-1 T1AM, pERK could be detected, but its levels were
not significantly different from those found in vehicle-
injected mice (data not shown). However, after treatment
with T1AM at doses of 0.132 and 0.04 mg·kg-1, that is, 10-fold
and 33-fold lower than the lowest dose proved to be effective
on memory acquisition and retention, pERK turned out to be
significantly higher than that observed in the vehicle group
(Figure 6).
Similar to pERK, pCREB, pAKT and c-fos were not signifi-
cantly modified in any brain area by 1.32 mg·kg-1 T1AM (data
not shown).
Figure 2
The object recognition task was performed on fed mice, which were
injected on day 2 with 1.32 mg·kg-1 T1AM or vehicle (n = 20 per
group). The retention session was performed 24 h later (A). Animal
movements in the arena (locomotor activity) were not significantly
different between the two groups (B). Results are expressed as mean
 SEM; ***P < 0.001 versus vehicle.
Figure 3
Mice were injected i.c.v. with T1AM (0.4, 1.32 and 4 mg·kg-1) or
vehicle and put on the hole-board platform. Movements and
exploratory activities were monitored as described in the Methods
section. Results are expressed as mean  SEM; n = 20 in each group;
***P < 0.001 and **P < 0.01 versus vehicle.
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Brain levels of thyroid hormones and T1AM
To exclude the possibility that the behavioural effects of
T1AM were affected by fluctuations of the thyroid hormones,
we measured T3, T4 and T1AM concentrations in the brains
of mice injected with 1.32 mg·kg-1 T1AM. Brain T3 and T4
levels, although quite variable, were consistent with previous
reports in rodents (Escobar-Morreale et al., 1996; Pinna et al.,
2002) and were not significantly modified after T1AM admin-
istration. The latter produced a 34-fold increase in brain
T1AM concentration. Taking into account brain weight, it
was calculated that less than 10% of the injected T1AM was
recovered in the brain after 30 min (Table 1). Although our
method allows the detection of T1AM catabolites such as
thyronamine, 3-iodothyroacetic acid and thyroacetic acid
(Saba et al., 2010), none of these compounds was observed,
suggesting that their brain concentrations were below the
limits of detection of the assay.
Discussion
We report for the first time that T1AM given i.c.v. behaves as
a memory enhancer in mice. This effect was achieved by
stimulating curiosity without modifying locomotor activity
or producing any analgesic effect. At the dosages active on
memory, T1AM also turned out to be hyperalgesic. Interest-
ingly, T1AM was similarly potent at stimulating memory and
curiosity, suggesting that increased exploratory activity is part
of the memory-enhancing effect, whereas it appeared to be
more potent at producing hyperalgesic and hyperglycaemic
effects. The latter therefore represents a sort of ‘fingerprint’ of
T1AM pharmacological properties.
In cell cultures and in isolated hearts, T1AM showed a
short half-life largely due to cellular uptake and oxidative
deamination to 3-iodothyroacetic acid (Saba et al., 2010).
This observation was confirmed in our experimental setting.
By 30 min after its i.c.v. injection, the brain T1AM concen-
tration had decreased from a nominal value of 231 pmol·g-1
to 13 pmol·g-1, consistent with its degradation and/or trans-
port into the systemic circulation (Manni et al., 2012). There-
fore, we wondered whether T1AM metabolite(s) might
contribute to its effects. To ascertain the role of oxidative
deamination, we repeated the passive avoidance and the hot
plate tests in animals pretreated with clorgyline, which has
been reported to increase T1AM concentration and to abolish
the production of deaminated derivatives, particularly of
3-iodothyroacetic acid (Saba et al., 2010; Manni et al., 2012).
Under these conditions, in the passive avoidance test, the
response to T1AM was markedly reduced and did not reach
the threshold of statistical significance. In the pain threshold
experiments, a significant response was still observed, but the
dose–response relationship was modified, as the dose of
Figure 4
(A) Mice were placed on the hot plate 30 min after i.c.v. injection of T1AM (0.13, 04, 1.32 and 4 mg·kg-1) or vehicle. The latency to respond to
the insult was evaluated as described in the Methods section. Results are expressed as mean  SEM; n = 20 in each group; *P < 0.05 and **P <
0.01 versus vehicle. (B) Mice were pretreated with clorgyline (2.5 mg·kg-1, i.p.), received either vehicle (Veh) or T1AM (0.13, 0.4 or 1.32 or
4 mg·kg-1) i.c.v and after 30 min were placed on the hot plate. The latency to respond to the insult was evaluated as described in the Methods
section. Results are expressed as mean  SEM; n = 10 in each group; ∧P < 0.05 versus vehicle without clorgyline (A) and *P < 0.05 versus vehicle
(with clorgyline).
Figure 5
Blood samples were collected from the tail vein of fed mice injected
i.c.v. with vehicle or with T1AM at dosages of 0.13, 0.4, 1.32 mg·kg-1
(n = 5 in each group). Glycaemia was measured by a glucorefrac-
tometer 30 min after i.c.v. injections. Results are expressed as mean
 SEM;*P < 0.05 versus vehicle.
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0.13 mg·kg-1, which was ineffective in the absence of
clorgyline, turned out to be hyperalgesic, while this effect
disappeared at higher doses. These results suggest either that
T1AM acts on rapid desensitizing targets, or that some of its
effects are mediated by deaminated derivatives, such as
3-iodothyroacetic acid. Although the latter could not be
detected in brain tissue, it should be pointed out that the
assay procedure was optimized to detect T1AM, and had a low
sensitivity for acid derivatives such as 3-iodothyroacetic acid
(Saba et al., 2010).
The interpretation of our findings is further complicated
by the observation that clorgyline per se induced a significant
reduction in the pain threshold. This might imply that
endogenous T1AM and/or its derivatives play a physiological
role in pain sensitivity but might also be explained by the
hypothesis that the response to T1AM is antagonized by
different aminergic systems. Notably, the effect of T1AM on
feeding was also modulated by clorgyline (Manni et al.,
2012), while behavioural effects of MAO inhibition have been
reported in different experimental models (Whitaker-Azmitia
et al., 1994). These issues deserve further investigation, and in
particular, it would be interesting to evaluate the effects of
i.c.v. injections of 3-iodothyroacetic acid.
T1AM has been reported to interact with trace amine-
associated receptor 1 (TA1 receptor), which is expressed
together with other members of the TA receptor family in
different brain regions (Zucchi et al., 2006). Interestingly,
TAAR genes are located in a region that is associated with
psychiatric disorders in linkage studies (Revel et al., 2011).
However, the role of TA receptors could not be directly dem-
onstrated in the present study because specific TA receptor
antagonists are not available. Different receptors might also
be involved, including a2 adrenoceptors, which have been
implicated in the pancreatic response to T1AM (Regard et al.,
2007).
ERK1/2 is a member of the family of MAPKs. The corre-
sponding signalling cascade has been reported to activate
cAMP-responsive element binding protein (CREB) and other
transcription factors, inducing the synthesis of proteins that
are required for the stabilization of new memories (Kida et al.,
2002; Pittenger et al., 2002) and the regulation of long-term
synaptic plasticity (Roberson and Sweatt, 1999). It is well
known that pERK2 and pAkt are cross-talking signals
involved in memory (Chen et al., 2008) and that pERK2 and
pAkt exert opposite effects on the expression and activity of
several transcription factors essential for the synthesis of new
proteins necessary for memory stabilization, including CREB
and c-fos (Peng et al., 2011). However, in this context, we
were unable to detect modifications of pERK, pCREB or c-fos
levels in any of the brain regions analysed following injection
Figure 6
Thirty minutes after i.c.v injection of T1AM (0.04, 0.13 mg·kg-1) or vehicle, mice (n = 3 per group) were killed and brain regions separated as
described in the Methods section. Immunodetection for pERK was carried out on protein lysates from each region separated on SDS-PAGE gels.
Results are the mean  SEM of the densitometry of three different gels. (A) Results of a typical experiment. (B) Cumulative results. *P < 0.05 versus
vehicle.
Table 1
Thyroid hormone and T1AM levels measured in the brains of mice
injected i.c.v. with T1AM (1.32 mgkg-1)
Treatment
T1AM
recovered
(pmol·g-1) T3 (ng·g-1) T4 (ng·g-1)
Vehicle (n = 6) 0.39  0.102 2.28  0.8 3.32  1.6
T1AM
(231 pmol·g-1
of brain;
n = 6)*
13.1  0.10 2.31  0.12 2.60  0.35
*Calculated considering the mean weight of brains as 0.432 
0.05 g.
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of 1.32 mg·kg-1 T1AM, while we detected significantly higher
pERK levels after exposure to lower T1AM doses, namely
0.04 and 0.13 mg·kg-1. This finding suggests that ERK1/2 sig-
nalling might be quickly and selectively activated by low
T1AM doses, whereas rapid desensitization occurs at higher
doses. Memory acquisition requires activation of receptor
cascades and synthesis of new proteins involved in memory
retention, and ERK phosphorylation appears to be a very
early event, which precedes gross behavioural effects, but its
specific causal role remains to be determined. The observa-
tion that T1AM activates pERK in brain regions such as the
amygdala and hippocampus might also be related to the
hyperalgesic response (Schicho et al., 2005; Ji et al., 2009; Liu
et al., 2012), which was elicited by low T1AM doses. The
signalling cascade leading to the hyperalgesic effect is
unknown, but T1AM might inhibit the release of analgesic
mediators (Hu et al., 2007) on the basis of its putative effect
on a2 adrenoceptors (Regard et al., 2007). In any case, the
hyperalgic and pro-learning effects cannot be accounted for
by changes in thyroid hormone concentration (Guasti et al.,
2007), which were not detected in brain tissue after T1AM
injection.
It has already been reported that i.c.v. injection of T1AM
modulates insulin and/or glucagon secretion and produces a
rise in plasma glycaemia (Manni et al., 2012). In the present
work, we observed that hyperglycaemia occurs even at the
dosage of 0.13 mg·kg-1, which is 10 times lower than that
previously used (Manni et al., 2012). There is no evidence
that moderate hyperglycaemia may produce behavioural
effects similar to those reported in the present investigation.
However, this issue deserves further investigation. In particu-
lar, it would be interesting to assess the behavioural effects of
T1AM on the diabetic/hypothyroid mouse.
To the best of our knowledge, this is the first report indi-
cating that the central effects of T1AM include the regulation
of complex behavioural functions involved in learning and
pain perception. These actions were associated with an
increase in local T1AM concentration of about one order of
magnitude, suggesting a novel potential physiological role of
endogenous T1AM and/or its deaminated derivative(s).
Thyroid hormones are essential for the development of mam-
malian brain and maintenance of optimal cognitive ability in
different periods of life (Bauer et al., 2008). In adulthood,
thyroid dysfunction leads to neurological and behavioural
abnormalities, including memory impairment. Adult-onset
hypothyroidism is also associated with clinically relevant
cognitive dysfunctions such as psychotic behaviour, halluci-
nations, confusion and learning defects (Rivas and Naranjo,
2007). Central hypothyroidism has been reported in patients
with Alzheimer’s disease (Sampaolo et al., 2005) and the
analysis of different experimental models suggests that the
effects on cognition rely on hippocampal modifications. In
the present work, we demonstrated that T1AM, an endog-
enous compound related to thyroid hormones, stimulates the
acquisition of memory in the mouse and that this effect does
not involve significant modifications of brain thyroid
hormone levels. It should be noted, thyroid hormone levels
found in the brains of our mice were similar to those dem-
onstrated by Escobar-Morreale et al. (1996) and Pinna et al.
(2002). Due to these novel effects, our results suggest that
pharmacological administration of T1AM might be useful in
neurodegenerative and endocrine disorders associated with
memory deficits.
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